IL6 and rheumatoid arthritis: Since IL-6 is also important in the pathophysiology of rheumatoid arthritis (RA), tocilizumab, an antibody against the IL-6 receptor has been shown to reduce pro-BNP and improve LV-function in RA patients without previously known HF (28, 29).